Scotia Biologics

Scotia Biologics is a private, revenue-generating contract research organization (CRO) specializing in custom antibody and protein production for the global biomedical research community. Founded by veterans of the successful biotech spin-out Haptogen Ltd., the company operates a fee-for-service business model, providing end-to-end project management from consultation to delivery of purified reagents or genetic material. Its core competency lies in applying integrated technologies—including bioinformatics, molecular biology, and immuno-technology—to engineer antibodies against challenging targets. While primarily a service provider, its deep expertise in therapeutic antibody development for hapten targets positions it with potential for future platform or therapeutic ventures.

Integrated suite of antibody engineering technologies including phage display, bioinformatics, molecular biology, and protein expression/purification systems, with specialty in generating antibodies to challenging antigens like haptens.

Scotia Biologics competes in the fragmented custom antibody services market against large, global CROs (e.g., GenScript, Bio-Techne) and many smaller specialists. Its key differentiator is the founders' proven track record in therapeutic-grade antibody engineering, particularly against haptens, rather than competing on price or high-throughput capacity for standard antigens.